EcoDrugPlus

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSAPOG00000005926
Gene Symbol: P2RY4
4 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSAPOG00000014384
Gene Symbol: P2RY6
4 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSAPOG00000015345
Gene Symbol: RAMP1
2 Cross references
190 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSAPOG00000008060
Gene Symbol: RAMP1
3 Cross references
183 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSAPOG00000023904
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSAPOG00000014876
Gene Symbol: LOC110957281
3 Cross references
207 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSAPOG00000024494
Gene Symbol: LOC110950702
2 Cross references
222 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta-Like

Ensembl ID : ENSAPOG00000010602
Gene Symbol: LOC110970585
2 Cross references
201 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSAPOG00000000722
Gene Symbol: RPTOR
3 Cross references
214 Possible Orthologues:

Renin-Like

Ensembl ID : ENSAPOG00000003412
Gene Symbol: LOC110956431
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSAPOG00000015142
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A

Ensembl ID : ENSAPOG00000017373
Gene Symbol: LOC110956088
3 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).